Experiments 26

Small Enough to Holdpart 2 of 2

Four Ways to Be Wrong

Chemotherapy instilled into the peritoneal cavity diffuses into tumor nodules while capillary washout clears it, limiting penetration to roughly a millimeter. Adjust drug, nodule size, and dwell time below, or inspect claims pre-registered by the research agent against the same solver.

Python · FastAPI · DuckDB · PharmacokineticsView source 

Four referees. One of them is arithmetic.

A core of 1.53 mm is never reached.

2 mm across the radius, drawn to scale
What you give
How big the nodule is
How long it sits

What the arithmetic says

It gets
0.47 mm
Never reached
1.53 mm
Of the volume
55.5%
Decay length
0.092 mm
Front settled
yes
Above killing
129×

The sink is mostly the capillaries, which carry off about forty times what the cells consume. This reproduces a published model exactly. It is not a measurement: published figures for the same question run from about twenty micrometres to five millimetres, and the spread is mostly about what each study counted as arriving. Read this as a scale.

Waking

  1. waiting 

 

 

No rules yet.

 

Sealed
0
Held
0
Broken
0
Refused
0

What the kernel reproduces

DrugIt saysPublishedIn band
Cisplatin0.453 mm0.36–0.49 mmyes
Paclitaxel0.593 mm0.54–0.75 mmyes

Steuperaert 2017, from its own cited parameters, with nothing fitted. Reproducing a model proves the code, not the physics, so this referee may refuse a claim but may not earn with one until it is gated against measured depths.

The four referees

RefereeAsksState
ReachCan it get there?not checked
KillDo the cells need it?not checked
MatterDoes it show up in people?not checked
LaterWhat will the trials report?not checked

Each gate is ground truth something else already fixed. Kill separates 1523 genes known to be needed by every cell from 726 known to be dispensable, at 0.9991 across 63 colorectal lines. Matter has to see checkpoint drugs run 5.07 times longer in mismatch-repair-defective disease, and stay quiet on a drug that should show nothing. Later has no opinion to check: a bet on a trial that has not reported is sealed and left open, sometimes for years. Reach passes neither, so it may refuse a claim and never earn with one.

What it has sealed

ClaimSaidFoundBits
 
 
 
 
 
 
Notes on how it works

Notes

Reaction-diffusion model

Intraperitoneal drug diffuses inward from the nodule surface while capillary washout clears it at rate k (roughly 40× cellular uptake), giving a characteristic decay length √(D/k). Effective penetration depth scales with that length times the log ratio of bath concentration to IC50. Once k · t exceeds ~3, the concentration profile reaches steady state and longer dwell times add negligible depth.

Literature calibration

Without parameter fitting, the solver matches published model depths for cisplatin (0.453 mm vs. 0.36–0.49 mm) and paclitaxel (0.593 mm vs. 0.54–0.75 mm). However, nine experimental penetration measurements in the literature span 20 µm to 5 mm (a 250× range) due to differing assay endpoints and systemic vascular delivery. Because a 0.5 mm prediction trivially falls inside that span, this referee can falsify bad arithmetic but cannot award discovery credit.

Knockout screen referee

The gene-essentiality referee scores 63 colorectal cell lines in DepMap, separating known core-essential and non-essential gene sets at AUROC 0.9991. However, only six screened lines derive from peritoneal metastases (representing five unique patients, below the pre-registered minimum sample size), and none appear in the PRISM drug-sensitivity screen. Per-site comparisons are therefore withheld automatically.

Pre-registered claims

The agent must seal every claim with a quantitative threshold and a probability before a referee executes. Claims are scored strictly on calibration and information gain over prior baseline bounds, and untestable claims are recorded as refused rather than retried.